Platelet aggregation and bleeding time abnormalities are reported in patients receiving p-lactam antibiotics (pLAs), although clinical bleeding most frequently occurs in chronically ill, malnourished patients. Although most pLAs bind to serum albumin, the relative influence of bound versus unbound pLAs on platelet function is unknown. We examined the effect of pLAs on the aggregation of gel-filtered platelets from normal subjects and on platelet-rich plasma (PRP) from hypoalbuminemic patients. Therapeutic concentrations of five BIAS were added to normal platelets at different albumin concentrations (1.5 to 4.5 g/dL). Inhibition of aggregation by the pLAs was inversely proportional to the albumin concentration, and most antibiotic-treated samples showed more than 50% inhibition at albumin levels below 2.0 g/dL. When -LACTAM ANTIBIOTICS (PLAs) may contribute to P bleeding episodes in patients by depleting vitamin K-dependent coagulation factors,',* interfering with fibrin polymeri~ation,~ or causing defects in platelet f~nction.~.' Despite well-documented platelet abnormalities in both normal and patient groups receiving PLAs,*.~ clinical bleeding primarily occurs in chronically ill and/or malnourished patients. Although platelet defects have been described at therapeutic concentrations for many some antibiotics produce defective platelet function in vitro only at concentrations greatly in excess of those used therapeutiPLAs reportedly inhibit platelet function by binding to the platelet surface, thereby preventing interaction of platelet agonists with their receptor^.".'^ Bleeding complications in hypoalbuminemic patients receiving PJAs are often associated with abnormal aggregation activity in vitro, suggesting that PLAs may exert an effect on platelet glycoprotein receptors.'' Although most PLAs bind to albumin as well as to other plasma proteins,'6 the effect of albumin concentration on the PLA inhibition of platelet function has received little attention. We investigated the PLA effect on platelet aggregation in the presence of varying albumin concentrations in an effort to explain the reports of bleeding in hypoalbuminemic patients receiving PLAs. We selected cephalothin, moxalactam, ceftriaxone, cefamandole, and penicillin to investigate PLA-mediated inhibition of platelet aggregation in platelets collected from 
PRPs from hypoalbuminemic patients were incubated with cephalothin, aggregation was completely inhibited, in contrast to samples from patients with normal albumin levels, and this decreased platelet aggregation was partially restored (25% to 75%) by increasing the albumin concentration above 4 patients with normal albumin levels and from hypoalbuminemic patients. In addition, we used [35S]-benzylpenicillin to study PLA binding to platelets and the effect of albumin on this binding.
METHODS AND MATERIALS
Platelet sources. Platelets were obtained from three groups of individuals. Group 1 consisted of platelet concentrates from normal blood donors obtained by automated plateletpheresis (Fenwal CS-3OOO; Baxter Health Care, Deerfield, IL). Group 2 consisted of platelet-rich plasma (PRP) samples from selected oncology patients, six with normal serum albumin (range, 3.0 to 4.6 g/dL) and four with low serum albumin levels (range, 2.5 to 2.8 g/dL; mean, 2.6 g/dL), studied to determine the effect of overnight incubation of platelets with cephalothin (200 kg/mL; Eli Lilly, Indianapolis, IN). In group 3, PRPs from patients with low levels of albumin (range, 2.6 to 3.0 g/dL; mean, 2.8 g/dL) receiving PLA were studied to determine the effects of adding human serum albumin in vitro, Two patients with uremia and one with cirrhosis who were receiving cephalothin (1 g six times daily) and one uremic patient receiving 250 mg of cephalothin orally four times daily were compared with one cirrhotic and six uremic patients not receiving PLAs. All patients and normal donors denied ingestion of aspirin, other nonsteroidal anti-inflammatory agents, or other plateletactive drugs for at least 2 weeks before this study. The hematocrits and platelet counts were similar in patients used for comparison (mean hematocrit of 22.5 in hypoalbuminemic patients and a mean of 20.0 in patients with normal albumin). Venous blood was drawn with minimal negative pressure from the antecubital vein of the arm not containing an arteriovenous fistula. Blood was drawn using the double plastic syringe technique and was immediately transferred into siliconized glass tubes at room temperature, containing sodium citrate at 3.8% (vollvol) final concentration. PRP was prepared by centrifuging the citrated blood at 16Og for 15 minutes at room temperature.
Measurement of the aggregation response of normal platelets treated with $ U s . [vol/vol] ) and centrifuged at 160g for 15 minutes at room temperature. Platelet counts ranged from 1.4 to 2.0 x 1@/mL. Cephalothin (in phosphate-buffered saline [PBS], pH 7.4) was added to a sample of PRP at a concentration of 200 kg/mL and an equal volume of PBS was added to a control sample. The PLA-treated and untreated samples were stored overnight in modified PL 732 platelet storage bags (Fenwal; Baxter Health Care) at 22°C with constant agitation. Platelet aggregation was measured as described above. The maximum slope of aggregation in response to 8 Fmol/L ADP was calculated for samples tested in duplicate.
In separate experiments, PRP from 10 hypoalbuminemic patients (four of whom were receiving cephalothin) was divided into two aliquots. Fatty acid-free human albumin (25 g/dL in 0.9% NaCI; Sigma) was added to one aliquot to adjust the albumin concentration to approximately 4.0 g/dL. An equal volume of 0.9% NaCl was added to the control aliquots. Platelet aggregation in response to 0.5 p,mol/L ADP was measured as described above.
A 15-pL suspension of Apiezon oil A (Biddle Co, Bluebell, PA) and n-butyl phthalate ( (final concentration, <OS%) was added to 200 pL samples of gel-filtered albumin-free platelets obtained from normal individuals?' Samples were inverted several times, incubated at 37°C for 15 minutes, and then centrifuged at 1,200g for 15 minutes. The supernatant was removed and the tip of the tube containing the pellet was excised. The pellet was solubilized in 500 pL of 1% sodium dodecyl sulfate. Radioactivity was measured after addition of Aquasol (Du Pont Co). Binding specificity was assessed by measuring the displacement of ['5S]-benzylpenicillin by 1,000-fold excess nonradioactive penicillin. Binding experiments were also performed on three gel-filtered plateletpheresis concentrates at different albumin levels. All samples were tested in quadruplicate.
Penicillin brnding experiments.
RESULTS

Aggregation response of normal platelets treated with PLA.
Aggregation was decreased significantly in gel-filtered platelets treated with any of the five PLAs tested at albumin concentrations less than 2.5 g/dL in the medium. An example of the relationship of platelet inhibition to albumin level is seen in Fig 1 when 8 wmol ADP was used as an agonist. The mean inhibition of aggregation for cephalothin in the five different platelet samples was 64% ? 35% for an albumin of 2 g/dL and 0% for an albumin of 4.0 g/dL. For most PLAs tested, platelet aggregation was either slightly affected or similar to the control sample (at the same albumin concentration but without PLA) when albumin levels exceeded 3.0 to 3.5 g/dL. Below this level, the inhibitory effect of PLAs was inversely related to albumin level in all samples. Similar effects were observed in washed platelets when 8 Kmol/L ADP or thrombin (0.1 to 1.0 U/mL) were used as agonists and in gel filtered platelets when collagen and epinephrine were used ( Aggregation response of platelets from hypoalbuminemic patients. Complete inhibition of platelet aggregation in response to 8 pmol/L ADP was achieved when platelets from four hypoalbuminemic individuals were incubated overnight with 200 pg/mL cephalothin (Fig 2B) . Little or no inhibition of ADP aggregation (8 pmol/L) occurred in platelets from six patients with albumin levels greater than 3.0 g/dL (Fig 2A) . The inhibition exhibited by the platelets in hypoalbuminemic plasma was partially reversible (25% to 75%) when the albumin levels were increased to 4.0 to 4.8 g/dL by the addition of 25 g/dL human albumin. Representative aggregation curves from a single subject are shown in Fig 3. When the albumin concentration of PRP from hypoalbuminemic patients (albumin range, 2.6 to 3.0 g/dL; mean, 2.8 g/dL) receiving cephalothin (1 g every 4 hours) was increased to 4.0 to 4.5 g/dL by the addition of human albumin, the platelet aggregation response to 0.5 pmol/L ADP increased (Fig 4A) . The maximum slope of platelet aggregation increased from a mean of 0.72 to 1.6 in patients receiving cephalothin when the albumin level was raised from an average of 2.8 g/dL to 4.2 g/dL. In contrast, the slope of aggregation decreased in PRP samples from patients with hypoalbuminemia who were not receiving PLA (Fig 4B) . The maximum slope of aggregation de- (Fig 6) . Similar results were obtained when stabilized albumin prepared for transfusion was substituted for fatty acid-free albumin. Platelets exposed overnight to radiolabeled penicillin continued to show decreased binding of penicillin at higher albumin levels. However, platelets incubated overnight bound less penicillin than those incubated for 15 minutes. This is most likely due to a loss of platelet integrity that occurs after gel filtration and storage in a non-gas-permeable container.
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Penicillin binding.
DISCUSSION
Bleeding episodes observed in patients who receive PLAs have been attributed to platelet dysfunction, hypoprothrombinemia, and the inhibition of fibrin polymerization. Factors that have been implicated in the increased risk of bleeding include thrombocytopenia, uremia, chemother- Platelet aggregation responses to 0.5 pmol/L ADP were tested using PRP obtained from four hypoalbuminemic patients (mean albumin, 2.8 g/dL) receiving cephalothin (1 g every 4 hours) (A) and six hypoalbuminemic patients receiving no antibiotics (B). Samples were split and the albumin levels of one of the pair were adjusted to approximately 4 g/dL; a similar volume of PBS was added to the control sample. Samples of PRP from patients not receiving antibiotics showed decreased aggregation after addition of albumin, a well-described phenomenon.'9 while the aggregation response of PRP from patients receiving PIAS increased.
apy, chronic illness, and malnutrition." The latter two conditions are often accompanied by hypoalbuminemia. Although serum albumin concentration influences the action of many drugs in vivo," no relationship between albumin concentration and @LA-induced platelet dysfunction has been reported.
In this study, the degree of inhibition of aggregation of gel-filtered platelets by @LAs was shown to be inversely related to albumin levels at concentrations below approximately 3.5 g/dL. This inhibition of function parallels the increased binding of radiolabeled penicillin to platelets at declining albumin levels. Platelet aggregation in patients with low albumin levels was inhibited after an overnight incubation with cephalothin (200 pg/mL), while platelets from patients with normal albumin levels exhibited no such inhibition. This inhibition of @LA-treated platelets was partially reversible after albumin levels were returned to normal by the addition of exogenous albumin.
In this study, platelets bound to the antibiotic in a specific manner and the amount of binding was inversely related to the albumin concentration. The protective effect of albumin is most likely a function of the avid binding of antibiotics to and the consequent depletion of free PLA available to the platelets. The binding of albumin to the antibiotic is reversible and drug molecules are in constant equilibrium between the bound and unbound ~t a t e .~' For penicillin, one molecule of drug binds to one molecule of albumin.% When concentrations of drug exceed the amounts that can be bound to albumin, or when concentrations of albumin decline, the levels of free unbound drug increase. Although it is clear that antibiotic bound to albumin has no antimicrobial a~tivity?~*~' the relationship of protein binding to other drug-related actions has not been explored. All PLAs used in this study For personal use only. on October 23, 2017. by guest www.bloodjournal.org From exhibit significant binding to p r~t e i n ,~~.~~ and the inhibition of platelet function by each PLA was blocked by albumin in a similar manner.
It is likely that PLAs exert their inhibitory effect by interfering with agonist interaction with platelet surface receptor^.'^^'^ This mechanism is supported by evidence that binding of an a-adrenergic antagonist, (3H)dihydroergocryptine, to platelet adrenergic receptors is reduced twofold, and (I4C)serotonin release is completely blocked after incubation of platelets with PLAs.I3 Evidence supporting reversible PLA binding to the platelet surface can be found in reports that platelet function returns to normal after exposed platelets are resuspended in PLA-free In our storage studies, in which platelets were stored under standard blood banking conditions, but in the presence of a therapeutic concentration of cephalothin, antibiotic-mediated platelet dysfunction was at least partially reversed by the addition of albumin. However, irreversible binding of radiolabeled penicillin to platelets and irreversible inhibition of platelet function after prolonged exposure to very high doses of penicillin (10 to 20 mmol/L) have been reported." Using similar conditions, we found that 24 hours of exposure to a high dose of penicillin G (5.4 mmol/L) in the presence of lowered albumin levels (1.27 to 1.45 g/dL; average, 1.36 g/L) impaired the aggregation response of platelets to thrombin even after removal of the antibiotic by washing, but no structural changes were observed in glycoprotein Ib or IIb by polyacrylamide gel electrophoresis and immunoblotting (data not shown). This finding is consistent with the report that in rat platelets treated with a variety of P U S , the loss of platelet function does not correlate with structural changes in surface glycoprotein^.^' This irreversible inhibition of platelet function seen at higher doses of penicillin probably is caused by a different mechanism of platelet membrane damage from the one responsible for the reversible inhibition seen at lower doses.
Our observation that inhibition of platelet aggregation by PLAs is inversely related to the albumin level suggests that albumin-bound antibiotic is unable to bind to platelets, or does so with less affinity than does unbound antibiotic. While our experiments do not directly address PLAinduced bleeding, we suspect that the increased frequency of bleeding reported in individuals with chronic illness who are treated with PLAs may be related to low albumin concentration. Our observations may further explain why PLA administration to normal subjects is rarely associated with platelet dysfunction or bleeding.
